National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:84

Article

Gelfand, Joel M.^1,2,3  Armstrong, April W.⁴  Bell, Stacie⁵  Anesi, George L.^2,3,6  Blauvelt, Andrew⁷  Calabrese, Cassandra⁸  Dommasch, Erica D.⁹  Feldman, Steven R.¹⁰  Gladman, Dafna^11,12  Kircik, Leon^13,14  Lebwohl, Mark¹³  Lo Re, Vincent, III^2,3,15  Martin, George¹⁶  Merola, Joseph F.¹⁷  Scher, Jose U.^18,19  Schwartzman, Sergio²⁰  Treat, James R.²¹  Van Voorhees, Abby S.²²  Ellebrecht, Christoph T.¹  Fenner, Justine¹³  Ocon, Anthony²³  Syed, Maha N.¹  Weinstein, Erica J.¹⁵  Gondo, George⁵  Heydon, Sue⁵  Koons, Samantha⁵  Ritchlin, Christopher T.²³ 

[1] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA

[5] Natl Psoriasis Fdn, Portland, OR USA

[6] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA

[7] Oregon Med Res Ctr, Portland, OR USA

[8] Cleveland Clin, Dept Rheumatol & Immunol, Cleveland, OH 44106 USA

[9] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA

[10] Wake Forest Sch Med, Dept Dermatol, Winston Salem, NC 27101 USA

[11] Toronto Western Hosp, Krembil Res Inst, Toronto, ON, Canada

[12] Univ Hlth Network, Univ Toronto, Toronto Western Hosp, Psoriat Arthrit Program, Toronto, ON, Canada

[13] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

[14] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA

[15] Univ Penn, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA

[16] Dermatol Associates, Boston, MA USA

[17] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[18] NYU, Dept Med, Div Rheumatol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA

[19] NYU, Langone Orthoped Hosp, New York, NY USA

[20] Hosp Special Surg, Dept Rheumatol, 535 E 70th St, New York, NY 10021 USA

[21] Childrens Hosp Philadelphia, Dept Pediat Dermatol, Philadelphia, PA 19104 USA

[22] Eastern Virginia Med Sch, Dept Dermatol, Norfolk, VA 23501 USA

[23] Univ Rochester, Med Ctr, Div Allergy, Immunol & Rheumatol Div, Rochester, NY 14642 USA

关键词: biologics;    COVID-19;    psoriasis;    psoriatic arthritis;    SARS-CoV-2;    vaccines;   

DOI  :  10.1016/j.jaad.2020.12.058

来源: Elsevier

【 摘 要 】

Objective: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. Study Design: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. Results: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. Limitations: The evidence behind many guidance statements is variable in quality and/or quantity. Conclusions: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

【 授权许可】

Free